These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8630880)

  • 1. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model.
    Davol P; Beitz JG; Mohler M; Ying W; Cook J; Lappi DA; Frackelton AR
    Cancer; 1995 Jul; 76(1):79-85. PubMed ID: 8630880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model.
    Davol P; Frackelton AR
    J Urol; 1996 Sep; 156(3):1174-9. PubMed ID: 8709341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
    Davol PA; Bizuneh A; Frackelton AR
    Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance.
    Davol PA; Frackelton AR
    Prostate; 1999 Aug; 40(3):178-91. PubMed ID: 10398280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo.
    Beitz JG; Davol P; Clark JW; Kato J; Medina M; Frackelton AR; Lappi DA; Baird A; Calabresi P
    Cancer Res; 1992 Jan; 52(1):227-30. PubMed ID: 1309225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-B16-F10 melanoma activity of a basic fibroblast growth factor-saporin mitotoxin.
    Ying W; Martineau D; Beitz J; Lappi DA; Baird A
    Cancer; 1994 Aug; 74(3):848-53. PubMed ID: 8039113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining suramin and a chimeric toxin directed to basic fibroblast growth factor receptors increases therapeutic efficacy against human melanoma in an animal model.
    Davol PA; Garza S; Frackelton AR
    Cancer; 1999 Nov; 86(9):1733-41. PubMed ID: 10547546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein.
    Farb A; Lee SJ; Min DH; Parandoosh Z; Cook J; McDonald J; Pierce GF; Virmani R
    Circ Res; 1997 Apr; 80(4):542-50. PubMed ID: 9118485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
    Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
    Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The basic fibroblast growth factor-saporin mitotoxin impairs in vivo skeletal regeneration following injury.
    Lefaucheur JP; Sébille A
    Neuromuscul Disord; 1993; 3(5-6):367-70. PubMed ID: 8186677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic effects of basic FGF and heparin binding EGF conjugated with cytotoxin saporin on vascular cell cultures.
    Chen C; Li J; Micko CJ; Pierce GF; Cunningham MR; Lumsden AB
    J Surg Res; 1998 Feb; 75(1):35-41. PubMed ID: 9614854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
    Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT
    J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
    Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
    Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
    Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
    Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor complexed to the cytotoxin saporin is growth inhibitory but not cytotoxic for embryonal carcinoma cells.
    Miller K; Wilder PJ; Rizzino A
    Cytotechnology; 1993; 13(2):69-78. PubMed ID: 7764580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative effect of basic fibroblast growth factor-saporin mitotoxin on keratocytes in culture.
    Wee WR; Parandoosh Z; Sakamoto T; Caton M; Nova M; McDonnell PJ
    Korean J Ophthalmol; 1996 Jun; 10(1):1-7. PubMed ID: 8755195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the heterogeneity of chemically conjugated targeted toxins: homogeneous basic FGF-saporin.
    Lappi DA; Matsunami R; Martineau D; Baird A
    Anal Biochem; 1993 Aug; 212(2):446-51. PubMed ID: 8214586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor.
    Lappi DA; Maher PA; Martineau D; Baird A
    J Cell Physiol; 1991 Apr; 147(1):17-26. PubMed ID: 1645359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor-2-toxin induced cytotoxicity: differential sensitivity of co-cultured vascular smooth muscle cells and endothelial cells.
    Lin PH; Ren D; Hirko MK; Kang SS; Pierce GF; Greisler HP
    Atherosclerosis; 1998 Apr; 137(2):277-89. PubMed ID: 9622271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biologic effects of growth factor-toxin conjugates in models of vascular injury depend on dose, mode of delivery, and animal species.
    Yu C; Cunningham M; Rogers C; Dinbergs ID; Edelman ER
    J Pharm Sci; 1998 Nov; 87(11):1300-4. PubMed ID: 9811480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.